ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1248

Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort

Rana Mongroo1, Samira Chowdhury2 and Steven Carsons2, 1Mount Sinai South Nassau Hospital, Mineola, NY, 2NYU Winthrop Hospital, Mineola, NY

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Sjögren's Syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Sjögren’s Syndrome Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjögren’s disease (SS) is characterized by the presence of antibodies against protein-small RNP complexes designated Ro/SSA and La/SSB. Both are included in the 2002 American-European Consensus Group Criteria (AECG) for SS, however La/SSB was excluded from the 2016 ACR-EULAR on the basis of findings1,2 demonstrating that SS patients seropositive for La/SSB without Ro/SSA (La/SSB) lacked an association with the phenotypic features of SS. We examined our single-center rheumatology division based primary SS cohort for the presence of patients SS displaying La/SSB. The phenotypic characteristics of this subset was compared to SS patients seropositive for La/SSB and Ro/SSA.

Methods: We retrospectively reviewed the charts of 318 patients for primary SS to determine the prevalence of La/SSB . Patients suspected of having secondary SS on the basis of the presence of another major connective tissue disorder were excluded. One hundred and twenty-eight fulfilled AECG. La/SSB were matched by age and symptom duration to an equal number of patients who were positive for La/SSB and Ro/SS-A. Groups were examined for sex, race, sicca symptoms, number of extraglandular manifestations (EGM), fulfillment of AECG, presence of ANA, RF, and IgG level at presentation. The difference between continuous variables was determined by the Wilcoxon ranked sign test. Differences in proportions among categorical variables was determined by Fisher’s exact test.

Results: Of the 318 evaluated charts, 17 had La/SSB without Ro/SSA (5.3%).  When compared to 17 with La/SSB and Ro/SSA, differences in clinical and laboratory characteristics were noted. La/SS-B displayed significantly fewer EGM, fulfilled AECG less often, and had significantly lower levels of RF, ANA and serum IgG. La/SSB were more often Caucasian (NS) (see Table 1 for details). The 5 La/SSB who fulfilled AECG represented 3.9% of the 128 patients fulfilling AECG; all 5 had positive labial salivary gland biopsies.

Conclusion: Consistent with results from the SICCA cohort1 and the OMRF cohort2, a small percentage (3.9%) of our rheumatology division based SS cohort who fulfilled SS criteria had La/SSB in the absence of Ro/SSA. In the majority of cases, La/SSB appears to constitute an atypical form of SS or represent a related but distinct autoimmune disorder.

References; 1Baer A. et al. Ann. Rheum. Dis. 2015:74(8); 1557-1561 2 Danda D. et al. Clin. Exp. Rheumatol. 2017:35; 438-444

Differences between Sjogren’s patients displaying La/SSB alone versus La/SSB with Ro/SSA


Disclosure: R. Mongroo, None; S. Chowdhury, None; S. Carsons, Novartis, 2.

To cite this abstract in AMA style:

Mongroo R, Chowdhury S, Carsons S. Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patients-seropositive-for-la-ssb-without-ro-ssa-differ-from-those-displaying-la-ssb-with-ro-ssa-in-a-single-center-sjogrens-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-seropositive-for-la-ssb-without-ro-ssa-differ-from-those-displaying-la-ssb-with-ro-ssa-in-a-single-center-sjogrens-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology